The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad541 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Kyueun Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Comparative Health Outcomes Policy and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Seasons, Influenza A Virus, H3N2 Subtype. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: AstraZeneca, GlaxoSmithKline, Pfizer.
Abstract (Originalsprache)
Background
Antigenic similarity between vaccine viruses and circulating viruses is crucial for achieving high vaccine effectiveness against seasonal influenza. New non-egg-based vaccine production technologies could revise current vaccine formulation schedules. We aim to assess the potential benefit of delaying seasonal influenza vaccine virus selection decisions.
Methods
We identified seasons where season-dominant viruses presented increasing prevalence after vaccine formulation had been decided in February for the Northern Hemisphere, contributing to their antigenic discrepancy with vaccine viruses. Using a SEIR (susceptible-exposed-infectious-recovered) model of seasonal influenza in the United States, we evaluated the impact of updating vaccine decisions with more antigenically similar vaccine viruses on the influenza burden in the United States.
Results
In 2014–2015 and 2019–2020, the season-dominant A(H3N2) subclade and B/Victoria clade, respectively, presented increasing prevalence after vaccine decisions were already made for the Northern Hemisphere. Our model showed that the updated A(H3N2) vaccine could have averted 5000–65 000 influenza hospitalizations in the United States in 2014–2015, whereas updating the B/Victoria vaccine component did not substantially change influenza burden in the 2019–2020 season.
Conclusions
With rapid vaccine production, revising current timelines for vaccine selection could result in substantial epidemiological benefits, particularly when additional data could help improve the antigenic match between vaccine and circulating viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comparative Health Outcomes Policy and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.
- Department of Family Medicine, School of Medicine, University of Pittsburgh, Pennsylvania.
- Seattle Children's Research Institute, Department of Pediatrics, University of Washington, Seattle.
- World Health Organization Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital.
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia.
ORCID-Profile: Kyueun Lee
Förderung
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- National Institute of Earth
- National Health and Medical Research Council
- NIAID NIH HHS
Zitieren
APA
Lee, K., Williams, K. V., Englund, J. A., & Sullivan, S. G. (2024). The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad541
Vancouver
Lee K, Williams KV, Englund JA, Sullivan SG. The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad541
BibTeX
@article{Lee2024,
author = {Lee, Kyueun and Williams, Katherine V and Englund, Janet A and Sullivan, Sheena G},
title = {The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad541}
}
EUVIMED